Pearl Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: GP MDI 28.8 μgDrug: GP MDI 14.4 μgDrug: GP MDI 7.2 μgDrug: Placebo MDI
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 1077
- Registration Number
- NCT03358147
- Locations
- 🇺🇸
Research Site, Greenfield, Wisconsin, United States
A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03311373
- Locations
- 🇺🇸
Pearl Investigative Site, Baltimore, Maryland, United States
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: GFF MDI (PT003)Drug: BGF MDI (PT010)Drug: BFF MDI (PT009)
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 416
- Registration Number
- NCT03262012
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03256552
- Locations
- 🇯🇵
Pearl Investigative Site, Toshima-ku, Tokyo-To, Japan
A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03250182
- Locations
- 🇺🇸
Research Site, Clearwater, Florida, United States
To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase 3
Withdrawn
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: BGF 320/14.4/9.6 µg MDIDrug: BFF 320/9.6 µg
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Registration Number
- NCT03081247
Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: PT003 (GFF MDI) 14.4/9.6 µgDrug: PT010 (BGF MDI) 320/14.4/9.6 µgDrug: PT010 (BGF MDI) 160/14.4/9.6 µg
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT03075267
- Locations
- 🇨🇳
Research Site, Shanghai, China
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
Phase 3
Completed
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: GP MDI (PT001) 14.4 μgDrug: FF MDI (PT005) 9.6 μg
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02937584
- Locations
- 🇧🇪
Research Site, Erpent, Belgium
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disorder
- Interventions
- Drug: FF MDI 9.6 μgDrug: BFF MDI 320/9.6 μgDrug: BFF MDI 160/9.6 μg
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 2389
- Registration Number
- NCT02766608
- Locations
- 🇷🇺
Research Site, Yekaterinburg, Russian Federation
A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disorder
- Interventions
- Drug: BFF MDI (PT009) 320/9.6 μgDrug: BFF MDI (PT009) 160/9.6 μgDrug: FF MDI (PT005) 9.6 μg
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 1876
- Registration Number
- NCT02727660
- Locations
- 🇬🇧
Research Site, Wishaw, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath